Last updated: May 29, 2026
VERELAN PM suppliers: Who manufactures extended-release verapamil PM and its supply chain inputs?
VERELAN PM is an extended-release verapamil product in a once-daily, capsule format. “PM” denotes a specific release profile and formulation concept using verapamil blended with an extended-release system. Supplier identification for VERELAN PM supply chain (drug substance, dosage-form components, and contract manufacturing) depends on the exact market (US vs. other geographies) and the current listed manufacturing/packaging sites for each NDA product label and application.
No complete, citable supplier roster for VERELAN PM can be produced from the information provided in the prompt.
Who are the contract manufacturers and packaging suppliers for VERELAN PM in the US?
Answer: Not determinable from the provided inputs.
What label sections list VERELAN PM manufacturing and packaging sites?
- NDA label sections commonly include “Manufactured for/Distributed by” and sometimes identify manufacturing sites.
- US regulatory traceability is normally obtained via:
- FDA drug label text (labeling and proprietary name)
- FDA SPL/DSCSA transaction history
- Orange Book “Manufacturers” and “Applicant/Holder” fields for the NDA
- ANDA reference listed drug (RLD) linkages for manufacturing references
Why supplier identification can change across lots
- VERELAN PM may shift between contract manufacturing organizations (CMOs) or fill-finish vendors due to:
- capacity reallocation,
- scale-up for demand spikes,
- formulation/packaging updates, and
- compliance-driven facility changes.
Which companies supply verapamil ER dosage-form components used in VERELAN PM?
Answer: Not determinable from the provided inputs.
What inputs matter for extended-release verapamil capsules
- Verapamil API supplier (drug substance)
- Extended-release matrix or coating system supplier (drug product component)
- Capsule shell supplier and sizing compatibility
- Film coat and ink/printing systems
- Blending and granulation excipients (controlled-release excipients, binder, disintegrant, lubricant)
- Packaging suppliers (bottles, caps, desiccants, induction seals)
- Analytical testing suppliers (in-process controls and release testing vendors, if outsourced)
What is the Orange Book status of VERELAN PM and how does it identify suppliers?
Answer: Not determinable from the provided inputs.
Where Orange Book listings show supply-chain participants
Orange Book records typically list:
- NDA number and applicant/holder
- dosage forms and strengths
- patent/market exclusivity
- sometimes RLD references and manufacturing context at the product level
When do VERELAN PM suppliers change, and what triggers new manufacturing sites?
Answer: Not determinable from the provided inputs.
Common triggers in ER capsule manufacturing
- Facility inspection outcomes leading to transfer of manufacture
- Regulatory CMC amendments (process changes, site transfers)
- Supplier consolidation of excipient or capsule shell systems
- Packaging format transitions (bottle/cap suppliers or child-resistant compliance)
Which generic/authorized suppliers compete with VERELAN PM and can reveal the supplier ecosystem?
Answer: Not determinable from the provided inputs.
How to use ANDA/RLD linkages for supplier inference
- ANDA applicants cite the RLD and often describe manufacturing site details for their ANDA product
- Comparison can show which CMOs are active in the same dosage form/market segment
- RLD labeling can indirectly confirm excipient and release-profile approach used in the originator
What manufacturing/IP barriers affect how suppliers can enter the VERELAN PM supply chain?
Answer: Not determinable from the provided inputs.
Typical barriers for extended-release solid oral formulations
- patent-protected release technology and specific formulation details
- process parameter windows for the extended-release system
- validated dissolution and release acceptance criteria
- stability and packaging qualification dependencies
Key Takeaways
- Supplier identification for VERELAN PM (manufacturing, packaging, API, and key excipient vendors) cannot be compiled into a complete and accurate list from the provided prompt.
- VERELAN PM supplier identification in the US normally requires NDA/label and regulatory database lookups that specify manufacturers, packagers, and application holders by site.
FAQs
- How do I identify the current manufacturer of VERELAN PM capsules from FDA labeling?
- Where can DSCSA transaction history reveal VERELAN PM supply-chain participants?
- Do Orange Book entries list VERELAN PM packaging sites and label manufacturing locations?
- How can ANDA/RLD references indirectly point to VERELAN PM’s formulation approach and suppliers?
- What CMC changes most often cause a transfer of VERELAN PM manufacturing sites?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
- FDA. DailyMed: Verelan PM (verapamil hydrochloride) label and SPL metadata. US FDA.
- FDA. DSCSA and product tracing resources. US FDA.
